Arcutis Biotherapeutics (ARQT) Profit After Tax (2019 - 2026)

Arcutis Biotherapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$11.8 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 53.3% year-over-year to -$11.8 million; the TTM figure through Mar 2026 stood at $13.3 million (down 74.51% YoY), while the FY2025 annual figure was -$37000.0, down 236.36% from the prior year.
• Profit After Tax for Q1 2026 stood at -$11.8 million, down from $33.5 million in the prior quarter.
• The five-year high for Profit After Tax was $128.7 million in Q4 2024, with the low at -$108.1 million in Q3 2022.
• The 5-year median for Profit After Tax is -$44.7 million (2023), against an average of -$32.0 million.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax plunged 89.63% in 2022, then jumped 796.01% in 2025.
• Arcutis Biotherapeutics' Profit After Tax stood at -$72.0 million in 2022, then increased by 6.71% to -$67.2 million in 2023, then jumped by 291.57% to $128.7 million in 2024, then sank by 73.97% to $33.5 million in 2025, then tumbled by 135.12% to -$11.8 million in 2026.
• Business Quant data shows ARQT's Profit After Tax at -$11.8 million in Q1 2026, $33.5 million in Q4 2025, and $7.4 million in Q3 2025.